Business
IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights
ProSense® system and disposables sales continue upward trend compared to the equivalent prior year periodExpanded regulatory footprint, growing body of
About this update from Icecure Medical Ltd.
[{"type":"text","content":"ProSense® system and disposables sales continue upward trend compared to the equivalent prior year periodExpanded regulatory footprint, growing body of evidenced-based data, and distribution agreements demonstrate an increasing acceptance of minimally invasive alternatives to standard of care cancer treatmentICE3 trial remains on track and expected to be completed in the first quarter of 2024 Conference call scheduled for today at 10 am ESTCAESAREA, Israel, Nov. 15, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (\"IceCure\" or the \"Company\"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the nine months ended September 30, 2023, as well as operational and recent corporate developments.\n\n\"First, I must make it clear that although Israel is engaged in a war with Hamas, IceCure remains more focused than ever on bringing our life-preserving technology to people around the world for improved healthcare outcomes. While our team and everyone in Israel is personally impacted by the war, IceCure continues to push ahead. We achieved several key objectives during the third quarter, including significant approvals in Brazil and Canada,\" stated Eyal Shamir, Chief Executive Officer.\n\"Furthermore, we believe the positive interim data from our ICE3 trial and the expanding body of independently conducted trials and published scientific data is an overwhelmingly strong testament to ProSense®'s path to widescale adoption across numerous indications, globally. While we have received clearance from the U.S. Food and Drug Administration (\"FDA\") for general minimally invasive cryoablation applications, including kidney, liver, and benign breast tumors, our primary objective is to gain marketing clearance for breast cancer, so that women will have an alternative treatment to the current standard of care, lumpectomy.\"\n\"With this aim, and with the U.S. representing the largest opportunity for ProSense®, we are continuing with the ICE3 trial, and we expect that it will be completed in the first quarter of 2024, when the final patient will have her five-year follow-up examination. In the interim, we have filed an appeal with the FDA regarding its decision on our De Novo filing...